Counterregulatory responses: Sustained-release isosorbide-5- mononitrate versus transdermal nitroglycerin

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 5, 1996, Pages 631-638

  Parker, John D ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Isosorbide 5 mononitrate; Plasma volume expansion; Systolic blood pressure; Transdermal nitroglycerin

Indexed keywords

CATECHOLAMINE; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE;

ADULT; ARTICLE; BLOOD VOLUME; CATECHOLAMINE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMPARISON; DRUG FORMULATION; DRUG RESPONSE; HEART RATE; HEMATOCRIT; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOLOGY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SUBLINGUAL DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; SYSTOLIC BLOOD PRESSURE; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADULT; BLOOD PRESSURE; BODY WEIGHT; CATECHOLAMINES; DELAYED-ACTION PREPARATIONS; DRUG TOLERANCE; HEART RATE; HEMATOCRIT; HUMANS; ISOSORBIDE DINITRATE; MALE; NITROGLYCERIN; RENIN; SINGLE-BLIND METHOD; SODIUM; VASODILATOR AGENTS;

EID: 0029907032     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199611000-00004     Document Type: Article

References (26)

1. Dalal JJ, Yao L, Parker JO. Nitrate tolerance: influence of isosorbide dinitrate on the hemodynamic and antianginal effects of nitroglycerin. J Am Coll Cardiol 1983;2:115-20.
2. Thadani U, Fung H-L, Dark AC, Parker JO. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose response relation during acute and sustained therapy. Am J Cardiol 1982;89:1074-80.
3. Reichek N, Priest C, Zimrin D, Sutton MS. Antinanginal effects of nitroglycerin patches. Am J Cardiol 1984;54:1-7.
4. Parker JO, Fung H-L, Ruggirello D, Stone JA. Tolerance to isosorbide dinitrate: rate of development and reversal. Circulation 1983;68:1074-80.
5. Parker JO. Nitrate therapy in stable angina pectoris. N Engl J Med 1987;316:1635-42.
6. Packer M. Clinical significance of nitrate tolerance in patients with chronic heart failure. Eur Heart J 1989;10(suppl A):20-5.
7. Abrams J. Clinical aspects of nitrate tolerance. Eur Heart J 1991;12(suppl E):42-52.
8. Packer M. What causes tolerance to nitroglycerine? The 100 year old mystery continues. J Am Coll Cardiol 1990;16:932-5.
9. Imhof P, Renwald D, Muller P, Howald H, Burkart F. Circulatory counter-regulations induced by continuous administration of nitroglycerin. J Pharmacol Exp Ther 1989;11:409-14.
10. Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991;84:2336-45.
11. Muiesan ML, Agabiti-Rosei E, Romanelli M, et al. Transdermal nitroglycerin efficacy in patients with chronic stable angina pectoris as related to sympathetic and renin-angiotensin-aldosterone activity. Eur Heart J 1992;13:15-21.
12. Katz RJ, Levy WS, Buffalo RL, Wasserman AG. Prevention of ni- trate tolerance with angiotensin-converting enzyme inhibitors. Circulation 1991;83:1271-7.
13. Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumeral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990;16:923-31.
14. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
15. Wagner F, Siefert F, Trenk D, Jahnchen E. Relationship between pharmacokinetics and haemodynamic tolerance to isosorbide-5-mononitrate. Eur J Clin Pharmacol 1990;38(suppl 1):S53-9.
16. Wisenberg G, Roks C, Nichol P, Goddard M. Sustained effect of and lack of development of tolerance to controlled-release isosorbide-5-mononitrate in chronic stable angina pectoris. Am J Cardiol 1989;64:569-76.
17. Parker JO. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate. Can J Cardiol 7:125-30.
18. Simon D, Hartmann DJ, Badouaille G, et al. Two-site direct immunoassay specific for active renin. Clin Chem 1992;38:1959-62.
19. Lis Y, Bennett D, Lambert G, Robson D. A preliminary double- blind study of intravenous nitroglycerin in acute myocardial infarction. Intensive Care Med 1984;10:179-84.
20. Parker JD, Farrell B, Fenton T, Parker JO. Effects of diuretic therapy on the development of tolerance during continuous therapy with nitroglycerin. J Am Coll Cardiol 1992;20:616-22.21.
21. Parker JD, Parker JO. Effect of therapy with an angiotensin-converting enzyme inhibitor on hemodynamic and counterregulatory responses during continuous therapy with nitroglycerin. J Am Coll Cardiol 1993;21:1445-53.
22. Parker JD, Parker AB, Farrell B, Parker JO. Intermittent transdermal nitroglycerin therapy: decreased anginal threshold during the nitrate free interval. Circulation 1995;91:973-8.
23. Chrysant SG, Classer SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993;72:1249-56.
24. Muller P, Imhof P, Burkart F, Chu L-C, Gerardin A. Human pharmacological studies of a new transdermal system. Eur J Clin Pharmacol 1982;22:473-80.
25. Yu DK, Williams RL, Benet LZ, Lin ET, Giesmg DH. Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing. Biopharm Drug Dispos 1988;9:557-65.
26. DeMots H, Classer SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989;13:786-8.